OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives $6.00 Consensus Price Target from Brokerages

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) has been assigned a consensus rating of “Hold” from the five brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $6.3333.

A number of equities analysts have recently issued reports on OKYO shares. B. Riley Financial assumed coverage on shares of OKYO Pharma in a research report on Monday, December 8th. They set a “buy” rating and a $5.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a research note on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of OKYO Pharma in a research note on Thursday, January 29th. Finally, Piper Sandler assumed coverage on shares of OKYO Pharma in a report on Friday. They set an “overweight” rating and a $7.00 price objective on the stock.

OKYO Pharma Trading Down 1.8%

OKYO opened at $1.67 on Friday. OKYO Pharma has a one year low of $1.03 and a one year high of $3.35. The business’s 50 day moving average price is $2.10 and its 200 day moving average price is $2.19.

OKYO Pharma (NASDAQ:OKYO) last posted its earnings results on Friday, January 30th. The company reported ($2.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($2.21). As a group, analysts predict that OKYO Pharma will post -0.17 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC bought a new stake in shares of OKYO Pharma in the 3rd quarter worth about $31,000. XTX Topco Ltd acquired a new position in OKYO Pharma during the 4th quarter valued at about $36,000. Finally, Renaissance Technologies LLC boosted its stake in OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after purchasing an additional 96,800 shares in the last quarter. Hedge funds and other institutional investors own 2.97% of the company’s stock.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.